Johnson & Johnson

J&J to buy cancer drug technology developer Firefly Bio for US$1 billion

JOHNSON & Johnson said on Monday (Jun 8) it will acquire biotech Firefly Bio for US$1 billion in cash, as it looks to expand its cancer drug pipeline.

J&J is one of 16 big pharmaceutical companies to have reached agreements to lower US drug prices, in exchange for exemptions from Trump-imposed tariffs.

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

The upbeat performance comes as the company faces multiple challenges, including tariff uncertainty on its medical devices unit

It's part of a strategy to cope with eroding sales for its major psoriasis drug.

J&J to buy Halda Therapeutics in US$3.05 billion cash deal

[NEW YORK] Johnson & Johnson has agreed to buy the cancer treatment biotech Halda Therapeutics for US$3.05 billion cash, part of a strategy to cope with eroding sales for its major psoriasis drug.

J&J is separately facing tens of thousands of lawsuits in the US, where claimants allege they were diagnosed with cancer after using baby powder and other company talc products.

J&J faces first UK lawsuits alleging its baby powder caused cancer

[LONDON] Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.

J&J would also announce plans for additional manufacturing facilities in the US and the expansion of current US sites in the coming months.

Johnson & Johnson to invest US$2 billion to boost US manufacturing as drug tariffs loom

[NEW YORK] Johnson & Johnson (J&J) said on Thursday (Aug 21) it would invest US$2 billion in North Carolina as it aims to expand its US manufacturing presence amid looming drug import duties proposed ...

J&J has been attempting to resolve the lawsuits through a subsidiary company’s bankruptcy, after two previous bankruptcy attempts failed in other courts.

US judge rejects J&J’s US$10 billion baby powder settlement

[NEW YORK] A US bankruptcy judge on Monday rejected Johnson & Johnson’s US$10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the t...

J&J’s deliberations come on the eve of the healthcare industry’s annual confab in San Francisco.

Johnson & Johnson is in talks to buy US$10 billion biotech Intra-Cellular

JOHNSON & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on treatments for central nervous system disorders, sources familiar with the matter said.

J&J faces lawsuits from more than 62,000 plaintiffs alleging its baby powder and other talc products were contaminated with asbestos.

J&J talc bankruptcy stays in Texas despite ‘forum-shopping’ opposition

A JOHNSON & Johnson (J&J) subsidiary can pursue its third attempt to resolve tens of thousands of lawsuits alleging its talc products caused cancer in a federal bankruptcy court in Texas, a judge rule...

The increase would boost the size of the settlement to more than US$9 billion paid over 25 years.

Johnson & Johnson adds US$1.1 billion to proposed talc settlement

JOHNSON & Johnson plans to pay an additional US$1.1 billion to resolve tens of thousands of legal actions alleging its baby powder and other talc products caused cancer, two people familiar with the m...